Triple therapy takes on bile duct cancer: hope for unresectable cases
NCT ID NCT05655949
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of radiation beads (Y-90), immunotherapy (durvalumab), and chemotherapy (gemcitabine and cisplatin) in 30 people with advanced bile duct cancer that cannot be removed surgically. The goal is to see if this mix can slow cancer growth and improve survival. Researchers are also monitoring for serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Y-90 radiation beads, durvalumab (immunotherapy), gemcitabine and cisplatin (chemotherapy)
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced bile duct cancer that cannot be removed by surgery.
- What could go wrong
- This is an early phase 2 trial with only 30 people, so results may not apply to everyone. The combination of treatments may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?